A T-cell player with backing from Roche takes next big step for BiTE drugs with 'on-off' switch to avoid toxicity
The bispecific T cell engager field is absolutely packed with big-name players who have crowded in despite some high-profile failures in the class. Now, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
